Shares of Moderna Inc. MRNA,
fell 0.9% in trading on Friday after the company said it was approving its COVID-19 vaccine in Japan in partnership with Takeda Pharmaceutical Co.
Takeda has submitted the new medicine application and the task is to import and distribute the vaccine from the company in Cambridge, Massachusetts. Takeda is also conducting the Phase 1/2 trial of the vaccine in adults who are at least 20 years old; enrollment ended in February. If approved, Takeda will distribute 50 million doses of Moderna’s dual-dose vaccine in Japan in the first half of 2021. Shares in Moderna have risen 372.3% over the past 12 months, while the broader S&P 500 SPX,
is 20.4% higher.
